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Summary: One hundred sera from intensive care patients, and 93 sera from endocrinological outpatients were used
for a comparison between two automated assays for free triiodothyronine (Enzymun Test, and Elecsys 2010, both
Boehringer Mannheim, Mannheim, Germany). In outpatients a good correlation between both methods was found
(r=0.932). In contrast, comparability between the two assays was poor in intensive care patients (r=0.75, after
exclusion of two outliers); significantly more values in the hypothyroid range were found with the Elecsys 2010
assay (n=83, compared with n=33 with the Enzymun Test; 2 test p=0.001). We conclude that routine measure-
ment of free triiodothyronine which has the theoretical advantage of quantifying the biologically active fraction of
thyroid hormones may have methodological limitations in severely ill patients.
Introduction
Measurement of free thyroid hormones has become part
of clinical laboratory routine in recent years. Determina-
tion of free triiodothyronine (fT3) provides a special
challenge since the binding to the transport proteins is
comparatively weak and the concentration of the free
hormone is only 0.01% of the total thyroxine concentra-
tion. There is no reference method established neither
for free nor for total triiodothyronine (T3). Triiodothyro-
nine is the biologically active thyroid hormone. It is
formed predominantly by intracellular deiodination of
thyroxine in the target tissues. In severely ill patients
substantial discrepancies have been reported for free
thyroid hormone levels determined either by routine
methods or by candidate reference methods such as
equilibrium dialysis and ultracentrifugation (1-3). Rou-
tine monitoring of low thyroid hormone concentrations
in intensive care patients may become increasingly rele-
vant, although the biological importance of alterations
in thyroid function and peripheral thyroid hormone me-
tabolism in severe illness is still a matter of debate (4).
However, a possible benefit of hormone treatment in
subgroups of intensive care patients has been reported
(5,6).
The aim of this study was to compare free thyroid
hormone concentrations in sera from intensive care
patients as determined by two assays run on automated
analyzers used in our laboratory.
Patients and Methods
One hundred sera from intensive care patients (medical intensive
care unit n=29; cardiosurgical intensive care unit n=31; neurosur-
gical intensive care unit n=20; surgical intensive care unit n=20)
consecutively sent for thyroid hormone determination were ana-
lysed. Thyrotropin (thyroidea stimulating hormone), free thyroxine
(fT4), and free triiodothyronine (fT3) were measured on two auto-
mated analyzers of the same manufacturer (Boehringer Mannheim,
Germany). Additionally, 93 sera from endocrinological outpatients
were included in the investigation. For method comparison simple
regression analysis and Pearson's correlation coefficient were de-
termined. The following assays were applied:
Enzymun tests. Assays for thyroid hormones: One-site immunoen-
zymometric assays (competition principle) with streptavidin-coated
tubes and photometrical quantification; in a first incubation the
sample is incubated with peroxidase-conjugated hormone-antibod-
ies; in a second step biotinylated triiodothyronine (or thyroxine) is
added, that binds to the streptavidin-coated tubes; free conjugated
antibodies are captured by this bound triiodothyronine (or thyrox-
ine), while unbound reagents and the sample are then removed by
aspiration; addition of a chromogenic substrate generates a colour
reaction which is quantified. Thyrotropin assay: Sandwich ELISA
with thyrotropin-antibody coated tubes, quantification of an enzy-
matic colour reaction.
Elecsys 2010 tests. Assays for thyroid hormones: Essentially the
same principle as hi the Enzymun assay; ferromagnetic micro-
beads are used as solide phase; antibodies are conjugated with
a ruthenium complex. The separation of bound and unbound
antibodies and of the sample is achieved by magnetic retention
of the beads in the measuring cell; an electrical voltage induces
electrochemiluminescence of the ruthenium-complex, which is
photomultiplied and quantified. Thyrotropin assay: Sandwich
ELISA. According to the manufacturer's information all antibod-
ies used in the Enzymun and Elecsys assays are identical (except
for the conjugate).
Reference values, as given by the manufacturer are as follows: TSH
Elecsys, 0.27-4.2 mU/1; TSH Enzymun, 0.25-3.1 mU/1. fT3
Elecsys, 4.3-8.3 pmol/1; fT3 Enzymun 5.4-9.3 pmol/1. fT4 Elec-
sys and fT4 Enzymun, both 11.8-24.6 pmol/1 (n=695 with the 5th-
95th percentile for Enzymun assays; n=503 with the 2.5 -97.5*
percentile for Elecsys assays).
Inter-assay imprecision of the Elecsys fT3 assay was tested over
fifteen series on two different analyzer machines using aliquoted
unpooled serum from one intensive care patient.
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The manufacturers recommendations for calibration were followed
closely, quality controls with control materials at two different
levels were performed in each run.
Results
We found a good correlation for thyrotropin and for free
thyroxine between the two assay systems in both outpa-
tients and intensive care patients ((for intensive care pa-
tients: r = 0.996, y=1.13x + 0.06 (TSH), and
r = 0.932, y = 0.91 χ + 0.15 (fT4); x: Elecsys, y: Enzy-
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Fig. 1 a) Free triiodothyronine (pmol/l): method comparison be-
tween the Elecsys 2010 (x) and Enzymun assay (y) in 100 intensive
care patients (after exclusion of two obvious outliers; lines indicat-
ing the respective reference range).
y = 0.96x + 3.39, r = 0.75
b) Free triiodothyronine (pmol/l): method comparison between the
Elecsys 2010 (x) and Enzymun assay (y) in 93 endocrinological
outpatients (lines indicating the respective reference range).
y = 0.89 x + 2.24, r = 0.932
(For values below 7.7 pmol/l (on the Elecsys system) a nearly iden-
tical correlation and equation was found (r = 0.942, and
y = 0.84 + 1.57)).
mun)). In contrast the correlation between the two fT3
assays was poor hi intensive care patients (fig. la))
(r = 0,36 for all values, r = 0.75 after exclusion of two
obvious outliers; y = 0.96 x + 2.21; x: Elecsys, y: En-
zymun; note different reference values); moreover the
value distribution of free triiodothyronine among inten-
sive care patients differed considerably (Elecsys fT3: low
n = 33, normal n = 61, high n = 5; median 2.8 pmol/l,
25th percentile 2.2 pmol/l, 75th percentile 3.4 pmol/l. En-
zymun JT3: low n = 83, normal n = 13, high n = 3; me-
dian, 5.8 pmol/l, 25th percentile 4.9 pmol/l, 75th percen-
tile 7.2 pmol/l). Α χ2 test (low fT3 values versus normal
values between both systems was significant
(p = 0.001). In contrast, in outpatients the correlation of
fT3 values was good (r = 0.973), with only one misclas-
sification between the two assays (fig. lb)).
In the intensive care patient group each one outlier of
free triiodothyronine measurement was identified and
reproduced on both systems compared :
Patient E. W. (82 years, male), multiple organ failure
due to septicaemia after cardiac surgery requiring
haemofiltration: fT3 Elecsys 19.0pmol/l, fT3 Enzymun
5.6 pmol/l, T3 Elecsys 1.2nmol/l (reference range
1.2-3.1 nmol/1), T3 Enzymun 1.4nmol/l (reference
range 1.2—2.7 nmol/1).
Patient G. B. (62 years, female), lysis therapy for myo-
cardial infarction: fT3 Elecsys 2.1 pmol/l, fT3 Enzymun
17.5 pmol/l, T3 Elecsys, 0.7, T3 Enzymun 0.6 nmol/1.
The interassay coeffecient of variation of the Elecsys
2010 fT3 assay was 8.1% at 3.4 pmol/l, and 20.9% at
1.1 pmol/l.
Discussion
The comparability of the two automated free triiodothy-
ronine assays was poor in intensive care patients but
good in outpatients. In the group of intensive care pa-
tients the frequency of subnormal free triiodothyronine
values was significantly different depending on which
method of the same manufacturer was used. In the ab-
sence of an established reference method, however, it is
not possible to decide whether the Enzymun test in fact
overestimates free triiodothyronine concentrations or the
Elecsys assay underestimates this analyte. The clinical
identification of the thyroid status in intensive care pa-
tients is difficult and often misleading.
Still undefined factors of endogenous or exogenous ori-
gin (e. g. common drugs like plasma expanders, or
increased levels of free fatty acids in patients on heparin
treatment) may be responsible for interferences with as-
says of free thyroid hormones in intensive care patients.
At least three mechanisms may be involved: The bound
to free (B/F) equilibrium or the avidity of hormone bind-
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ing may be altered both in vivo and ex vivo; the binding
characteristics of analytical antibodies may be altered;
and though signal generation takes place in a sample-
free medium in both assays substances that interfere
with the signal generation (enzymatic colour reaction
and electrochemiluminescence) may be bound to the as-
say solid phase. It is possible that the two tests compared
here differ in their sensitivity to these putative interfer-
ing factors.
Outliers of free triiodothyronine results occured in both
systems among intensive care patients (n=2). These re-
sults were reproducible. Thus spurious results have to
be encountered in the percent range in intensive care pa-
tients.
In the hypothyroid range, precision of the Elecsys fT3
assay is limited with a functional sensitivity (coefficient
of variation ^  20%) of about 1.1 pmol/1 as evidenced by
inter-assay imprecision study.
In summary, our results indicate that free triiodothyro-
nine assays may be more prone to still undefined in-
terfering factors in sera of intensive care patients than
other thyroid hormone assays and that as a consequence
routine measurement of free triiodothyronine may have
substantial methodological limitations in hospitalized
patients. Further clinically based evaluation in intensive
care patients seems necessary for each test if clinical
decisions like hormone substitution are based on free
triiodothyronine test results in the low measuring range.
At present the only clear indication for triiodothyronine
measurement is the determination of isolated triiodothy-
ronine-hyperthyroidism, and the monitoring of triiodo-
thyronine-substitution therapy.
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